Li H et al. (2014), Primary concomitant EGFR T790M mutation predict...

ECB-ART-50062

Onco Targets Ther 2014 Mar 05;7:513-24. doi: 10.2147/OTT.S60122.

Show Gene links Show Anatomy links

Primary concomitant EGFR T790M mutation predicted worse prognosis in non-small cell lung cancer patients.

Li H , Hu H , Wang R , Pan Y , Wang L , Li Y , Zhang Y , Ye T , Zhang Y , Li B , Shen L , Sun Y , Chen H .

???displayArticle.abstract???
PURPOSE: We performed this analysis to improve the understanding of the clinicopathological characteristics and clinical outcome of non-small cell lung cancer (NSCLC) patients harboring the primary epidermal growth factor receptor (EGFR) T790M mutation along with activating EGFR mutation. METHODS: Resected tumors from 1903 NSCLC patients were analyzed for mutation in EGFR, as well as KRAS (Kirsten rat sarcoma viral oncogene homolog), BRAF (v-raf murine sarcoma viral oncogene homolog B), HER2 (human epidermal growth factor 2), PIK3CA (phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha), and EML4 (echinoderm microtubule associated protein like 4)-ALK (anaplastic lymphoma receptor tyrosine kinase) fusion. Fluorescence in situ hybridization was performed to define EGFR and c-MET (met proto-oncogene gene amplification. Expression of PIK3CA and p-Akt (phosphorylated protein kinase B) were tested using immunohistochemistry. Clinical and pathological data, including sex, age at diagnosis, stage, tumor differentiation, smoking history, histological subtype, relapse-free and overall survival, were further analyzed. RESULTS: In all, 16 NSCLC patients were found to harbor primary EGFR T790M mutation, including 14 adenocarcinomas and two adenosquamous carcinomas, accounting for 2.04% of all the EGFR mutant cases and 0.84% of the total. No c-MET amplification was found to coexist with primary EGFR T790M. Fewer EGFR copy-number variations were found in samples harboring EGFR T790M mutations compared with those in patients with exon 19 deletions and L858R. Overall survival was significantly shorter for patients harboring EGFR T790M mutation than it was for patients with exon 19 deletions (logrank P=0.008). When taking patients harboring EGFR L858R or exon 19 deletions as one group, the overall survival was also significantly longer than that in patients with T790M mutation (logrank P=0.012). There was no significant difference in relapse-free survival among three subgroups of patients. CONCLUSION: Our study described the clinicopathological and molecular characteristics of NSCLC patients harboring primary EGFR T790M mutations. Its value of being a predictor for worse prognosis was established. Primary EGFR T790M mutation is a rare event in NSCLC cases, but the therapeutic strategies for this subtype of patients should be precisely considered.

???displayArticle.pubmedLink??? 24729716
???displayArticle.pmcLink??? PMC3979794
???displayArticle.link??? Onco Targets Ther

???attribute.lit??? ???displayArticles.show???

References [+] :

Amann, Aberrant epidermal growth factor receptor signaling and enhanced sensitivity to EGFR inhibitors in lung cancer. 2005, Pubmed

Amann, Aberrant epidermal growth factor receptor signaling and enhanced sensitivity to EGFR inhibitors in lung cancer. 2005, Pubmed
Arcila, Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay. 2011, Pubmed
Bean, MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. 2007, Pubmed
Bell, Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR. 2005, Pubmed
Cappuzzo, Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. 2005, Pubmed
Engelman, MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. 2007, Pubmed
Engelman, ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines. 2005, Pubmed
Godin-Heymann, Oncogenic activity of epidermal growth factor receptor kinase mutant alleles is enhanced by the T790M drug resistance mutation. 2007, Pubmed
Goldstraw, The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. 2007, Pubmed
Hirsch, Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study. 2005, Pubmed
Inukai, Presence of epidermal growth factor receptor gene T790M mutation as a minor clone in non-small cell lung cancer. 2006, Pubmed
Jackman, Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib. 2006, Pubmed
Kobayashi, EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. 2005, Pubmed
Kosaka, Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib. 2006, Pubmed
Li, Comprehensive analysis of epidermal growth factor receptor gene status in lung adenocarcinoma. 2011, Pubmed
Morita, Combined survival analysis of prospective clinical trials of gefitinib for non-small cell lung cancer with EGFR mutations. 2009, Pubmed
Mukohara, Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations. 2005, Pubmed
Mulloy, Epidermal growth factor receptor mutants from human lung cancers exhibit enhanced catalytic activity and increased sensitivity to gefitinib. 2007, Pubmed
Oxnard, New strategies in overcoming acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer. 2011, Pubmed
Oxnard, Screening for germline EGFR T790M mutations through lung cancer genotyping. 2012, Pubmed
Pao, Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. 2005, Pubmed
Prudkin, Germ-line and somatic presentations of the EGFR T790M mutation in lung cancer. 2009, Pubmed
Riely, Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib. 2006, Pubmed
Sanger, DNA sequencing with chain-terminating inhibitors. 1977, Pubmed
Sordella, Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. 2004, Pubmed
Sun, Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases. 2010, Pubmed
Takano, Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer. 2005, Pubmed
Tracy, Gefitinib induces apoptosis in the EGFRL858R non-small-cell lung cancer cell line H3255. 2004, Pubmed
Travis, International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. 2011, Pubmed
Vikis, EGFR-T790M is a rare lung cancer susceptibility allele with enhanced kinase activity. 2007, Pubmed

	Figure 1. Overall survival in patients harboring different kinds of EGFR mutation subtypes.Abbreviation: EGFR, epidermal growth factor receptor.
	Figure 2. Relapse-free survival in patients harboring different kinds of EGFR mutation subtypes.Abbreviation: EGFR, epidermal growth factor receptor.
	Figure 3. Case number of PIK3CA, p-Akt-positive expression and EGFR, c-MET gene copy number variations.Abbreviations: c-MET, met proto-oncogene; EGFR, epidermal growth factor receptor; FISH, fluorescence in situ hybridization; p-Akt, phosphorylated protein kinase B; PIK3CA, phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha.